Literature DB >> 18545245

Non-endocrine late complications in children after allogeneic haematopoietic SCT.

M Faraci1, A N Békássy, V De Fazio, A Tichelli, G Dini.   

Abstract

Non-endocrine events represent a heterogeneous group of complications occurring in children who survive long term after haematopoietic SCT. This review highlights the late sequel in a growing child. The preparative regimen itself with high-dose chemotherapy and/or radiotherapy (TBI) or the treatment given before the transplant procedure may cause organ damage with permanent sequel. Immune reconstitution and chronic GvHD have crucial role in occurrence of clinical abnormalities and late severe infections. Autoimmune syndromes may occur after use of novel transplant modalities (cord blood transplantation, reduced intensity conditioning regimen and haploidentical T-cell-depleted SCTs). Exposure to chemo- and/or radiotherapy increases the risk of second malignant neoplasms. Surveillance strategy focusing on each potential complication risk at continuous follow-up will allow vigilant post transplant care. Each paediatrician must be well versed in appropriate monitoring of these complications. Guidelines and recommendations are provided for serious problems occurring at follow-up, which must rapidly be identified so that appropriate intervention can be initiated. To achieve cure at a lowest possible price in terms of suffering and cost expenditures for health care is an extended frontier of paediatric haematopoietic SCT and biggest challenge for a paediatrician.

Entities:  

Mesh:

Year:  2008        PMID: 18545245     DOI: 10.1038/bmt.2008.55

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  14 in total

1.  Long-term systolic function in children and young adults after hematopoietic stem cell transplant.

Authors:  S J Rotz; C E Dandoy; M D Taylor; S Jodele; J L Jefferies; A Lane; J A El-Bietar; A W Powell; S M Davies; T D Ryan
Journal:  Bone Marrow Transplant       Date:  2017-07-17       Impact factor: 5.483

2.  The importance of long-term follow-up in pediatric hematopoietic stem cell transplantation.

Authors:  D A Jacobsohn
Journal:  Bone Marrow Transplant       Date:  2015-04-13       Impact factor: 5.483

3.  Monitoring of Busulphan Concentrations in Children Undergone Hematopoietic Stem Cell Transplantation: Unicentric Experience over 10 years.

Authors:  Maura Faraci; Carmine Tinelli; Edoardo Lanino; Stefano Giardino; Massimiliano Leoni; Marta Ferretti; Elio Castagnola; Monica Broglia; Annalisa De Silvestri; Daniela Di Martino; Antonella Bartoli
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-04       Impact factor: 2.441

4.  Long-term health-related outcomes in survivors of childhood cancer treated with HSCT versus conventional therapy: a report from the Bone Marrow Transplant Survivor Study (BMTSS) and Childhood Cancer Survivor Study (CCSS).

Authors:  Saro H Armenian; Can-Lan Sun; Toana Kawashima; Mukta Arora; Wendy Leisenring; Charles A Sklar; K Scott Baker; Liton Francisco; Jennifer Berano Teh; George Mills; F Lennie Wong; Joseph Rosenthal; Lisa R Diller; Melissa M Hudson; Kevin C Oeffinger; Stephen J Forman; Leslie L Robison; Smita Bhatia
Journal:  Blood       Date:  2011-06-07       Impact factor: 22.113

5.  Adverse health events and late mortality after pediatric allogeneic hematopoietic SCT-two decades of longitudinal follow-up.

Authors:  M Wilhelmsson; A Vatanen; B Borgström; B Gustafsson; M Taskinen; U M Saarinen-Pihkala; J Winiarski; K Jahnukainen
Journal:  Bone Marrow Transplant       Date:  2015-03-23       Impact factor: 5.483

6.  The injured heart: early cardiac effects of hematopoietic stem cell transplantation in children and young adults.

Authors:  S J Rotz; T D Ryan; S Jodele; J L Jefferies; A Lane; A Pate; R Hirsch; J Hlavaty; A E Levesque; M D Taylor; M Cash; K C Myers; J A El-Bietar; S M Davies; C E Dandoy
Journal:  Bone Marrow Transplant       Date:  2017-04-10       Impact factor: 5.483

7.  Should busulfan therapeutic range be narrowed in pediatrics? Experience from a large cohort of hematopoietic stem cell transplant children.

Authors:  M Philippe; S Goutelle; J Guitton; X Fonrose; C Bergeron; P Girard; Y Bertrand; N Bleyzac
Journal:  Bone Marrow Transplant       Date:  2015-09-21       Impact factor: 5.483

8.  Patient-reported outcomes in survivors of childhood hematologic malignancies with hematopoietic stem cell transplant.

Authors:  Hsiu-Ju Yen; Hesham M Eissa; Neel S Bhatt; Sujuan Huang; Matthew J Ehrhardt; Nickhill Bhakta; Kirsten K Ness; Kevin R Krull; D Kumar Srivastava; Leslie L Robison; Melissa M Hudson; I-Chan Huang
Journal:  Blood       Date:  2020-05-21       Impact factor: 22.113

9.  Neurological complications of transplantation: part I: hematopoietic cell transplantation.

Authors:  Amy A Pruitt; Francesc Graus; Myrna R Rosenfeld
Journal:  Neurohospitalist       Date:  2013-01

10.  Health status of childhood leukemia survivors who received hematopoietic cell transplantation after BU or TBI: an LEA study.

Authors:  F Bernard; P Auquier; I Herrmann; A Contet; M Poiree; F Demeocq; D Plantaz; C Galambrun; V Barlogis; J Berbis; F Garnier; N Sirvent; J Kanold; P Chastagner; H Chambost; G Michel
Journal:  Bone Marrow Transplant       Date:  2014-02-17       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.